TJGC, Elastic, Quoin, and SMST lead market gains on tech deals, strong earnings, clinical data, and inverse ETF moves.

TJGC Group surged 24.69% on potential AI and robotics licensing talks, though the deal is still preliminary. Elastic rose 19.31% after beating Q1 2027 earnings expectations and raising its guidance. Quoin Pharmaceuticals gained 18.72% following positive Phase 2/3 clinical trial results and a $50 million financing plan. The inverse leveraged ETF SMST jumped 14.55% due to a sharp drop in Strategy Inc. shares. These moves highlight varied catalysts including earnings beats, clinical progress, speculative tech interest, and market momentum.